New data for both approved and investigational oncology compounds from Janssen Research & Development, LLC will be presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting. In total, 19 company-sponsored abstracts have been accepted for presentation, including for abiraterone acetate, daratumumab and ibrutinib. Most notably, Phase 3 pivotal trial results for abiraterone acetate will be featured in the ASCO Press Briefing on Saturday, June 3^rd and have been selected for inclusion in the Plenary Session on Sunday, June 4^th.

“We are focused on delivering therapies that not only treat cancer, but aim to intercept and eliminate disease,” said Peter F. Lebowitz, M.D., Ph.D., Oncology Therapeutic Area Head, Janssen Research & Development. “We continue to investigate ways in which our medicines can potentially benefit patients at earlier stages of their disease, and we are excited to share emerging data at ASCO for our therapies.”

Key data presentations from our oncology pipeline, include:

• abiraterone acetate: Findings from the LATITUDE pivotal trial will provide the first look at Phase 3 results assessing abiraterone acetate plus prednisone in newly diagnosed patients with high-risk metastatic hormone-naïve prostate cancer (mHNPC) (Abstract LBA3).

  • These data will be featured in an ASCO Press Briefing from 8 – 9 a.m. CDT on Saturday, June 3^rd and presented in the Plenary Session from 2:40 – 2:55 p.m. CDT on Sunday, June 4^th. Data from the LATITUDE trial have also been selected for the Best of ASCO program.

• daratumumab: Follow-up data from the CASTOR/POLLUX pivotal trials will provide additional insights into the longer-term efficacy of the immunotherapy daratumumab in combination with lenalidomide plus dexamethasone (DRd), or bortezomib plus dexamethasone (DVd), in relapsed or refractory patients with multiple myeloma, based on cytogenetic risk (Abstract 8006).

  • These data will be presented in an Oral Presentation from 11:45 – 11:57 a.m. CDT on Sunday, June 4^th.

• daratumumab: Phase 1b study results from the MMY1001 trial will provide an early look at the safety and efficacy of daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (KRd) for patients with newly diagnosed multiple myeloma. These data examine daratumumab combination therapy for patients at an earlier stage of disease (Abstract 8000).

  • These data will be presented in an Oral Presentation from 9:45 – 9:57 a.m. CDT on Sunday, June 4^th, and have been accepted for the Best of ASCO program.

• ibrutinib: Up to four-year follow-up data from the pivotal Phase 3 RESONATE study will shed light on the longer-term efficacy and safety of treatment with the BTK inhibitor ibrutinib in previously treated patients with chronic lymphocytic leukemia (CLL), including those with genetic abnormalities deletion 11q and deletion 17p, which put patients at risk for poor outcomes (Abstract 7510).

  • These data will be presented in a Poster Discussion Session from 1:15 – 2:30 p.m. CDT on Monday, June 5^th.